@article{Wang2022, 
author = {Dong Wang and Xiao-ling Cai and Xu Lin and Jing Zheng and Yun-li Wu and Xian-e Peng},
title = {Hepatoprotective drugs for prevention of liver injury resulting from anti-tuberculosis treatment: A meta-analysis of cohort studies},
year = {2022},
journal = {Infectious Medicine},
volume = {1},
number = {3},
pages = {154-162},
keywords = {Hepatoprotective drug, Tuberculosis, Liver injury, Meta-analysis},
url = {https://www.sciopen.com/article/10.1016/j.imj.2022.07.003},
doi = {10.1016/j.imj.2022.07.003},
abstract = {BackgroundThe incidence of liver injury caused by anti-tuberculous (TB) drugs is very high. However, owing to a lack of sufficient evidence, preventive use of hepatoprotective drugs is not yet recommended. Therefore, we aimed to assess the protective effect of hepatoprotective drugs for anti-TB drug-induced liver injury.MethodsWe conducted a literature search in China Biology Medicine disc, China National Knowledge Infrastructure, WanFang, Chinese Scientific and Technological Journal, PubMed, Cochrane Library, Web of Science, and Embase. We performed meta-analysis using R 4.0 and Review Manager 5.3 software.ResultsA total of 18 studies involving 3589 patients from 2 groups were included. Use of hepatoprotective drugs contributed to a lower incidence of liver injury as compared with conventional anti-TB treatment alone (relative risk [RR] = 0.39, 95% confidence interval [CI]: 0.28–0.53, p < 0.001). In subgroup analysis, significant protective effects were noted for mild liver injury (RR = 0.30, 95% CI 0.15–0.58), moderate (or severe) liver injury (RR = 0.35, 95% CI 0.19–0.65), and liver injury within 2–4 weeks (RR = 0.37, 95% CI 0.19–0.71). We also found a statistically significant difference in the incidence of drug withdrawal (RR = 0.58, 95% CI 0.34–0.97, p = 0.040).ConclusionsOur results demonstrate that hepatoprotective drugs are effective in preventing liver injury in patients receiving anti-TB treatment, to some extent.}
}